Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial
Cabozantinib in advanced adrenocortical carcinoma showed promising efficacy with a manageable and anticipated safety profile. Further prospective studies with cabozantinib alone and in combination with immune checkpoint therapy are ongoing.